CONFIRM Trial

CONFIRM is a double blind randomised phase III trial comparing nivolumab (anti‐PD‐1 antibody) monotherapy versus placebo for one year. The treatment allocation ratio is 2:1 (treatment: placebo).

Existing samples:

  • Mesothelioma, malignant (morphologic (abnormality)

Contact Information

Email:
confirmtrial@soton.ac.uk
Address:

Southampton Clinical Trials Unit
Southampton General Hospital
Tremona Road
Southampton
Hampshire
SO16 6YD
UK

Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A